320 related articles for article (PubMed ID: 34727172)
41. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
42. ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.
Childress MA; Himmelberg SM; Chen H; Deng W; Davies MA; Lovly CM
Mol Cancer Res; 2018 Nov; 16(11):1724-1736. PubMed ID: 30002191
[TBL] [Abstract][Full Text] [Related]
43. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
44. ALK-positive lymphoma: a single disease with a broad spectrum of morphology.
Benharroch D; Meguerian-Bedoyan Z; Lamant L; Amin C; Brugières L; Terrier-Lacombe MJ; Haralambieva E; Pulford K; Pileri S; Morris SW; Mason DY; Delsol G
Blood; 1998 Mar; 91(6):2076-84. PubMed ID: 9490693
[TBL] [Abstract][Full Text] [Related]
45. Are all ALK variants created equal? Clinicopathologic features and outcomes: a propensity-matched study.
Batra U; Sharma M; Nathany S; Jain P; Soni S; Mehta A
Int J Clin Oncol; 2021 Jul; 26(7):1221-1228. PubMed ID: 33844110
[TBL] [Abstract][Full Text] [Related]
46. Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing.
Xia Y; Zhang L; He W; Pan H; Fang J; Cui G
Cancer Biol Ther; 2023 Dec; 24(1):2271212. PubMed ID: 37906510
[TBL] [Abstract][Full Text] [Related]
47. Pseudosarcomatous myofibroblastic proliferations of the urinary bladder are neoplasms characterized by recurrent FN1-ALK fusions.
Acosta AM; Demicco EG; Dal Cin P; Hirsch MS; Fletcher CDM; Jo VY
Mod Pathol; 2021 Feb; 34(2):469-477. PubMed ID: 32908253
[TBL] [Abstract][Full Text] [Related]
48. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
49. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
50. Failure of crizotinib based systemic treatment in ALK positive histiocytosis involving the central nervous system: a case report and literature review.
He Q; Zhang W; Li Q
BMC Pediatr; 2022 May; 22(1):308. PubMed ID: 35614430
[TBL] [Abstract][Full Text] [Related]
51. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
52. ALK-Rearranged Epithelioid Mesenchymal Neoplasm: Expanding the Spectrum of Tyrosine Kinase-Altered Mesenchymal Tumors.
Gestrich CK; Davis JL; Biederman L; John I; Alaggio R; Giovannoni I; Arnold MA; Shenoy A; Tchakarov A; Al-Ibraheemi A
Mod Pathol; 2023 Dec; 36(12):100334. PubMed ID: 37726067
[TBL] [Abstract][Full Text] [Related]
53. Spindle cell variant of epithelioid cell histiocytoma (spindle cell histiocytoma) with ALK gene fusions: Cases series and review of the literature.
Kazlouskaya V; Ho J; Jedrych J; Karunamurthy A
J Cutan Pathol; 2021 Jul; 48(7):837-841. PubMed ID: 33217002
[TBL] [Abstract][Full Text] [Related]
54. Cutaneous Non-Neural Granular Cell Tumors Harbor Recurrent ALK Gene Fusions.
Cohen JN; Yeh I; Jordan RC; Wolsky RJ; Horvai AE; McCalmont TH; LeBoit PE
Am J Surg Pathol; 2018 Sep; 42(9):1133-1142. PubMed ID: 30001233
[TBL] [Abstract][Full Text] [Related]
55. Pediatric Mesothelioma With ALK Fusions: A Molecular and Pathologic Study of 5 Cases.
Argani P; Lian DWQ; Agaimy A; Metzler M; Wobker SE; Matoso A; Epstein JI; Sung YS; Zhang L; Antonescu CR
Am J Surg Pathol; 2021 May; 45(5):653-661. PubMed ID: 33399341
[TBL] [Abstract][Full Text] [Related]
56. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
[TBL] [Abstract][Full Text] [Related]
57. [Clinicopathological features and prognosis of ALK-positive Spitz tumors].
Ren J; Ren M; Kong YY; Cai X; Kong JC
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):215-219. PubMed ID: 30831648
[No Abstract] [Full Text] [Related]
58. Impact of ALK Inhibitors in Patients With
Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223
[TBL] [Abstract][Full Text] [Related]
59. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract][Full Text] [Related]
60. PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Li T; Zhang F; Wu Z; Cui L; Zhao X; Wang J; Hu Y
Lung Cancer; 2020 Jan; 139():146-150. PubMed ID: 31794921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
